Qureight

A Cambridge company that uses AI to measure lung and heart scans so drug trials can show whether treatments work.

About Qureight

Qureight provides imaging and measurement services for clinical trials, focused on lung and heart conditions. Its offer includes imaging CRO services (running the scan side of a trial), AI-based lung biomarkers that track how a disease progresses, and data tools such as synthetic control arms. Medicine developers already use it in several fibrotic lung diseases.

We did not find a formal mission statement. A July 2026 announcement quotes co-founder and chief executive Dr Muhunthan Thillai describing a "critical demand to accelerate clinical trials", and a new board member saying that AI powered by real-world data "can accelerate discovery and transform clinical research".

Qureight is based in Cambridge, UK. The same July 2026 announcement shows it is still trading and growing; it says new resources will help scale the commercial team.

We did not find a description of the culture, values or headcount.

The announcement lists no open roles, and we found no graduate scheme, internship or apprenticeship. Check Qureight's own careers page, and think about backgrounds in data science, imaging, biology or clinical research.

What they do

• {'desc': 'Runs the imaging side of clinical trials.', 'title': 'Imaging CRO services'}
• {'desc': 'Measures lung scans to track disease progression.', 'title': 'AI lung biomarkers'}
• {'desc': 'Includes synthetic control arms for trials.', 'title': 'Data science tools'}

Key facts

• Based in Cambridge, UK
• Focus on lung and heart conditions
• Co-founder and CEO: Dr Muhunthan Thillai
• Announcement dated 29 July 2026

Website: www.qureight.com